La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !
Verve Therapeutics Bilan de santé
Santé financière contrôle des critères 3/6
Informations clés
0%
Ratio d'endettement
US$0
Dette
Ratio de couverture des intérêts | n/a |
Argent liquide | US$575.95m |
Fonds propres | US$546.09m |
Total du passif | US$154.82m |
Total des actifs | US$700.91m |
Mises à jour récentes de la santé financière
We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Recent updates
Earnings Release: Here's Why Analysts Cut Their Verve Therapeutics, Inc. (NASDAQ:VERV) Price Target To US$25.78
Aug 10We're Not Very Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Rate
Jul 12Why Verve Therapeutics Deserves A Spot On Your Watchlist
Jun 13Broker Revenue Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher
May 14The Verve Therapeutics, Inc. (NASDAQ:VERV) First-Quarter Results Are Out And Analysts Have Published New Forecasts
May 12Verve Therapeutics Stock Remains A Hold After VERVE-101 Enrollment Pause
Apr 03Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 28Verve's Proof-Of-Concept Data Doesn't Inspire Confidence
Feb 13Vectoring In On Verve Therapeutics
Jan 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
Jun 07Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth
Feb 24We Think Verve Therapeutics (NASDAQ:VERV) Can Afford To Drive Business Growth
Nov 09Verve Therapeutics: Cathie Wood Adds To ARKK
Sep 20Why did Verve Therapeutics stock jump today? Data on high cholesterol candidate
Aug 23Verve Therapeutics falls postmarket on $200M stock offering
Jul 20More CRISPR In Human Subjects
Jul 14Here's Why We're Not Too Worried About Verve Therapeutics' (NASDAQ:VERV) Cash Burn Situation
May 11Verve Therapeutics: Early-Stage Biotech With A Large Market
Apr 16Verve Therapeutics (NASDAQ:VERV) Is In A Good Position To Deliver On Growth Plans
Jan 31Verve Therapeutics: Pioneering Cardiovascular Medicine Using The Power Of Gene Editing
Aug 24Verve Therapeutics jumps 75% in its first day of trading
Jun 17Analyse de la situation financière
Historique et analyse du ratio d'endettement
Niveau d'endettement: VERV est sans dette.
Bilan
Analyse des pistes de trésorerie
Pour les entreprises qui ont été en moyenne déficitaires dans le passé, nous évaluons si elles disposent d'au moins un an de trésorerie.
Piste de trésorerie stable: VERV dispose d'une piste de trésorerie suffisante pour plus de 3 ans sur la base de son flux de trésorerie disponible actuel.
Prévisions de trésorerie: VERV dispose d'une marge de trésorerie suffisante pour 2.5 ans si le flux de trésorerie disponible continue de diminuer à un taux historique de 34.4 % chaque année.